Alembic's generic venetoclax, therapeutically equivalent to Venclexta, received final FDA approval for CLL/SLL and newly diagnosed AML.
Quiz|Articles|November 6, 2026
OncLive Weekly News Quiz (11/6/2026): Did You Miss Crucial Hematologic, Lung, and Desmoid Tumor Updates?
Author(s)OncLive Staff
Fact checked by: Riley Kandel
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The FDA granted priority review to a supplemental new drug application for zanubrutinib (Brukinsa) plus rituximab (Rituxan) in adults with previously untreated mantle cell lymphoma, based on data from the phase 3 MANGROVE trial (NCT04002297). By what percentage did the regimen reduce the risk of progression or death vs bendamustine (Treanda) plus rituximab?
Advertisement
Related to this article
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
Yale experts address borderline resectability, perioperative chemoimmunotherapy, pCR-guided adjuvant therapy, and osimertinib in early-stage NSCLC.
The FDA granted priority review to an sNDA for zanubrutinib plus rituximab in untreated mantle cell lymphoma.
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.
Phase 3 SAFFRON data support EU and Japanese filings for savolitinib plus osimertinib in EGFR-mutated NSCLC with MET overexpression or amplification.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5